HARMONY BIOSCIENCES HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.32 USD | +1.35% |
|
-0.27% | -9.23% |
| Apr. 11 | Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy | MT |
| Apr. 03 | Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms | MT |
Presenter SpeechUnknown Analyst (Analysts)Welcome, everyone. I'm [ Sangibita ] with JPMorgan H...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action (MOA) designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a wake-promoting neurotransmitter. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
29.32
USD
Average target price
41.5
USD
Spread / Average Target
+41.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.23% | 1.67B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- HRMY Stock
- News Harmony Biosciences Holdings, Inc.
- Transcript : Harmony Biosciences Holdings, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05
